Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 1
2013 1
2014 3
2015 2
2016 1
2017 3
2018 6
2019 3
2020 4
2021 5
2022 4
2023 17
2024 10
2025 12
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review.
Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, Bauer BA, Mohabbat AB. Yang J, et al. J Pain Res. 2023 Mar 21;16:1017-1023. doi: 10.2147/JPR.S395457. eCollection 2023. J Pain Res. 2023. PMID: 36974308 Free PMC article. Review.
Low-dose naltrexone (LDN) has been increasingly used as an off-label treatment option in FM. ...Overall, LDN was found to be effective in the symptomatic management of FM, and of the 78% of included studies that evaluated for safety, no severe adverse events …
Low-dose naltrexone (LDN) has been increasingly used as an off-label treatment option in FM. ...Overall, LDN was found …
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS, Fishman MA. Kim PS, et al. Curr Pain Headache Rep. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0. Curr Pain Headache Rep. 2020. PMID: 32845365
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltrexone in the treatment of chronic pain. RECENT FINDINGS: Recent pre-clinical uses and clinical studies further elucidate th …
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose …
The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.
Patten DK, Schultz BG, Berlau DJ. Patten DK, et al. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. Pharmacotherapy. 2018. PMID: 29377216 Review.
It is the purpose of this review to examine the evidence of the safety, tolerability, and efficacy of low-dose naltrexone for use in chronic pain and inflammatory conditions. Currently, evidence supports the safety and tolerability of low-dose …
It is the purpose of this review to examine the evidence of the safety, tolerability, and efficacy of low-dose naltrexone …
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K, Vrooman B. Toljan K, et al. Med Sci (Basel). 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. Med Sci (Basel). 2018. PMID: 30248938 Free PMC article. Review.
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opio …
Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory …
Low-dose naltrexone in the treatment of fibromyalgia: A systematic review and narrative synthesis.
Aitcheson N, Lin Z, Tynan K. Aitcheson N, et al. Aust J Gen Pract. 2023 Apr;52(4):189-195. doi: 10.31128/AJGP-09-22-6564. Aust J Gen Pract. 2023. PMID: 37021443 Free article.
METHOD: A systematic literature search was conducted using the key words 'naltrexone', 'fibromyalgia', 'fibrositis', 'chronic pain' and 'neurogenic inflammation'. RESULTS: Manual exclusion led to the identification of 21 papers, with only five prospective controlled …
METHOD: A systematic literature search was conducted using the key words 'naltrexone', 'fibromyalgia', 'fibrositis', 'chronic …
Efficacy of Low-Dose Naltrexone in Treating Patients with Fibromyalgia: systematic Review and Meta-Analysis.
Ologunowa A, Otoo MN, Caffrey AR, Buchanan A, Eze UJ, Vyas A. Ologunowa A, et al. J Pain Palliat Care Pharmacother. 2025 Sep;39(3):363-373. doi: 10.1080/15360288.2025.2496526. Epub 2025 Apr 24. J Pain Palliat Care Pharmacother. 2025. PMID: 40272382
Low-dose naltrexone (LDN) has demonstrated mixed efficacy in treating fibromyalgia. This systematic review and meta-analysis aimed to evaluate the efficacy of LDN for fibromyalgia. ...This suggests that LDN may not provide significant clinical b …
Low-dose naltrexone (LDN) has demonstrated mixed efficacy in treating fibromyalgia. This systematic review and m …
Low-dose naltrexone as a treatment for chronic fatigue syndrome.
Bolton MJ, Chapman BP, Van Marwijk H. Bolton MJ, et al. BMJ Case Rep. 2020 Jan 6;13(1):e232502. doi: 10.1136/bcr-2019-232502. BMJ Case Rep. 2020. PMID: 31911410 Free PMC article.
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn's disease, fibrom …
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Al …
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J, Parkitny L, McLain D. Younger J, et al. Clin Rheumatol. 2014 Apr;33(4):451-9. doi: 10.1007/s10067-014-2517-2. Epub 2014 Feb 15. Clin Rheumatol. 2014. PMID: 24526250 Free PMC article. Review.
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflamma …
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, C …
Therapeutic Uses and Efficacy of Low-Dose Naltrexone: A Scoping Review.
Leiber KK, Parker RW. Leiber KK, et al. Cureus. 2025 Mar 24;17(3):e81086. doi: 10.7759/cureus.81086. eCollection 2025 Mar. Cureus. 2025. PMID: 40271304 Free PMC article. Review.
Low-dose naltrexone (LDN) has been suggested as a novel treatment option for several conditions and is of increasing interest due to its potential ability to address certain medical conditions that lack effective treatments or frequently rely on the use of op …
Low-dose naltrexone (LDN) has been suggested as a novel treatment option for several conditions and is of increasing in …
Complex Regional Pain Syndrome: A Comprehensive Review.
Taylor SS, Noor N, Urits I, Paladini A, Sadhu MS, Gibb C, Carlson T, Myrcik D, Varrassi G, Viswanath O. Taylor SS, et al. Pain Ther. 2021 Dec;10(2):875-892. doi: 10.1007/s40122-021-00279-4. Epub 2021 Jun 24. Pain Ther. 2021. PMID: 34165690 Free PMC article. Review.
Female gender is a risk factor for developing CRPS. Other risk factors include fibromyalgia and rheumatoid arthritis. Unfortunately, the pathogenesis of CRPS is not yet clarified. ...Antioxidant treatment has also shown some promise. Other pharmacotherapies include low …
Female gender is a risk factor for developing CRPS. Other risk factors include fibromyalgia and rheumatoid arthritis. Unfortunately, …
75 results